PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment.
Lorenzo BianchiFrancesco CeciEleonora BalestrazziFrancesco CostaMatteo DroghettiPietro PiazzaAlessandro PissaviniMassimiliano PresuttiAndrea FarolfiRiccardo MeiPaolo CastellucciGiorgio GandagliaAlessandro LarcherDaniele RobestiAlexandre MottrieAlberto BrigantiAlessio Giuseppe MorgantiStefano FantiFrancesco MontorsiRiccardo SchiavinaEugenio BrunocillaPublished in: Cancers (2023)
≤ 0.04) Conclusion: Patients who underwent second-line PSMA-guided MDT experienced higher MFS and CRPC-FS compared to men who received conventional management.